1. Clinical safety and activity from a phase 1 study of LOXO-101, a selective TRKA/B/C inhibitor, in solid-tumor patients with NTRK gene fusions. (February 2017) Authors: Hong, D.S.; Dowlati, A.; Burris, H.A.; Lee, J.J.; Brose, M.S.; Farago, A.F.; Bauer, T.M.; Taylor, M.; Shaw, A.T.; Smith, S.; Nanda, N.; Cruikshank, S.; Cox, M.C.; Doebele, R.C. Journal: European journal of cancer Issue: Volume 72(2017)Supplement 1 Page Start: S148 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 29LBA Entrectinib (RXDX-101), an oral pan-Trk, ROS1, and ALK inhibitor in patients with advanced solid tumors harboring gene rearrangements. (September 2015) Authors: Siena, S.; Drilon, A.E.; Sai-Hong Ou, I.; Farago, A.F.; Patel, M.; Bauer, T.M.; Hong, D.; Liu, S.V.; Lee, J.; Patel, R.; Schechet, L.; Luo, D.; Chow Maneval, E.; Multani, P.S.; De Braud, F.G. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S724 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 7LBA Safety, activity, and response durability assessment of single agent rovalpituzumab tesirine, a delta-like protein 3 (DLL3)-targeted antibody drug conjugate (ADC), in small cell lung cancer (SCLC). (September 2015) Authors: Pietanza, M.C.; Spigel, D.; Bauer, T.M.; Ready, N.E.; Glisson, B.S.; Morgensztern, D.; Robert, F.; Salgia, R.; Kochendorfer, M.; Patel, M.; Strickland, D.K.; Govindan, R.; Burris, H.A.; Rudin, C.M.; Dylla, S. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S712 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 367 Effects of alisertib (MLN8237), an investigational Aurora A kinase inhibitor (AAKi), on the QTc interval in patients (pts) with advanced malignancies. (September 2015) Authors: Zhou, X.; Nemunaitis, J.; Pant, S.; Bauer, T.M.; Patel, M.; Sarantopoulos, J.; Lockhart, A.C.; Goodman, D.; Zhang, B.; Ullmann, C. Dansky; Mould, D.R.; Venkatakrishnan, K. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S76 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 342 A Phase Ib/II study of alpelisib (BYL719) and ganitumab (AMG 479) in adult patients with selected advanced solid tumors. (September 2015) Authors: Juric, D.; Rodón, J.; Bauer, T.M.; Wainberg, Z.; Tolaney, S.; Modi, S.; Martín, A. González; Hengelage, T.; Melendez, M.; Choudhury, S.; Nauwelaerts, H.; Bedard, P.L. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S68 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Milademetan, an oral MDM2 inhibitor, in well-differentiated/ dedifferentiated liposarcoma: results from a phase 1 study in patients with solid tumors or lymphomas. (October 2020) Authors: Gounder, M.M.; Bauer, T.M.; Schwartz, G.K.; LoRusso, P.; Kumar, P.; Kato, K.; Tao, B.; Hong, Y.; Patel, P.; Hong, D. Journal: European journal of cancer Issue: Volume 138(2020)Supplement 2 Page Start: S3 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Overall responses and survival in RCC on pegilodecakin with anti-PD-1. (March 2019) Authors: Naing, A.; Infante, J.R.; Wong, D.J.; Korn, W.M.; Aljumaily, R.; Papadopoulos, K.P.; Autio, K.A.; Pant, S.; Bauer, T.M.; Drakaki, A.; Daver, N.G.; Hung, A.; Verma, R.; Ratti, N.; McCauley, S.; Van Vlasselaer, P.; Tannir, M.; Oft, M. Journal: European journal of cancer Issue: Volume 110(2019)Supplement 1 Page Start: S1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗